Combined treatment of silibinin with either sorafenib or EGFR tyrosine kinase inhibitors enhances growth inhibitory effects in hepatocellular carcinoma cells

키워드

참고문헌 (47)

1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
2. Fenoglio L, "Epidemiology, clinical-treatment patterns and outcome in 256hepatocellular carcinoma cases", World J Gastroenterol, 19, pp.3207~3216 (2013)
3. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
4. Cheng AL, "Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
5. Cohen GS, "Multidisciplinary management of hepatocellular carcinoma : A model for therapy", J Multidiscip Healthc 20, 6, pp.189~195 (2013)
6. Pawlik TM, "Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma", J Clin Oncol, 29, pp.3960~3967 (2011)
7. Park JW, "Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma", J Hepatol, 56, pp.1336~1342 (2012)
8. Kudo M, "Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma", Eur J Cancer, 47, pp.2117~2127 (2011)
9. Zhao JD, "Maintenance of sorafenib following combined therapy of three-dimensional conformal radiation therapy", intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma : A phase I, Radiat Oncol 201, pp.2010, 5[DOI]
10. Morisaki T, "Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro", Anticancer Res, 33, pp.1387~1395 (2013)
11. Kelley RK, "Temsirolimus combined with sorafenib in hepatocellular carcinoma : A phase I dose-finding trial with pharmacokinetic and biomarker correlates", Ann Oncol, 24, pp.1900~1907 (2013)
12. Alsaied OA, "Sorafenib and triptolide as combination therapy for hepatocellular carcinoma", Surgery, 156, pp.270~279 (2014)
13. Kroll DJ, "Milk thistle nomenclature : Why it matters in cancer research and pharmacokinetic studies", Integr Cancer Ther, 6, pp.110~119 (2007)
14. Gazak R, "Silybin and silymarin--new and emerging applications in medicine", Curr Med Chem, 14, pp.315~338 (2007)
15. Singh RP, "Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis", Cancer Epidemiol Biomarkers Prev, 12, pp.933~939 (2003)
16. Tyagi A, "Inhibition of retinoblastoma protein (rb) phosphorylation at serine sites and an increase in rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: Role in prostate cancer prevention", Mol Cancer Ther, 1, pp.525~532 (2002)
17. Deep G, "Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: Targeting VEGF-VEGFR signaling", PLoS One, 7, pp.e34630~ (2012)
18. Singh RP, "Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft", Carcinogenesis, 28, pp.2567~2574 (2007)
19. Hogan FS, "Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer", J Surg Res, 143, pp.58~65 (2007)
20. Sangeetha N, "Silibinin modulates biotransforming microbial enzymes and prevents 1,2-dimethylhydrazine-induced preneoplastic changes in experimental colon cancer", Eur J Cancer Prev, 18, pp.385~394 (2009)
21. Mohan S, "Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells", Biochem Biophys Res Commun, 320, pp.183~189 (2004)
22. Mallikarjuna G, "Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and akt signaling", Cancer Res, 64, pp.6349~6356 (2004)
23. Tyagi A, "Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages", Carcinogenesis, 25, pp.1711~1720 (2004)
24. Tyagi AK, "Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells", Biochem Biophys Res Commun, 312, pp.1178~1184 (2003)
25. Singh RP, "Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving downregulation of survivin", Clin Cancer Res, 14, pp.300~308 (2008)
26. Chu SC, "Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2", Mol Carcinog, 40, pp.143~149 (2004)
27. Varghese L, "Silibinin efficacy against human hepatocellular carcinoma", Clin Cancer Res, 11, pp.8441~8448 (2005)
28. Lah JJ, "Effects and mechanisms of silibinin on human hepatoma cell lines", World J Gastroenterol, 13, pp.5299~5305 (2007)
29. Rho JK, "Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation", Mol Cancer Ther, 9, pp.3233~3243 (2010)
30. Altekruse SF, "Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008", Hepatology, 55, pp.476~482 (2012)
31. El-Serag HB, "Treatment and outcomes of treating of hepatocellular carcinoma among medicare recipients in the united states : A population-based study", J Hepatol, 44, pp.158~166 (2006)
32. Lee JK, "An update on clinical trials in the treatment of advanced hepatocellular carcinoma", J Clin Gastroenterol, 47, pp.S16~S19 (2013)
33. Mokhtari MJ, "Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line", Cell Biol Int, 32, pp.888~892 (2008)
34. Raina K, "Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model", Cancer Res, 68, pp.6822~6830 (2008)
35. Singh RP, "Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels", Cancer Res, 62, pp.3063~3069 (2002)
36. Roy S, "P21 and P27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells", Mol Cancer Ther, 6, pp.2696~2707 (2007)
37. Tyagi A, "Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells", Pharm Res, 25, pp.2143~2150 (2008)
38. Hannay JA, "Silibinin : A thorny therapeutic for EGF-R expressing tumors?", Cancer Biol Ther, 2, pp.532~533 (2003)
39. Sharma Y, "Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells", Mol Carcinog, 30, pp.224~236 (2001)
40. Singh RP, "Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis", Cancer Res, 68, pp.2043~2050 (2008)
41. Flaig TW, "A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients", Invest New Drugs, 25, pp.139~146 (2007)
42. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
43. Daveau M, "Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma", Mol Carcinog, 36, pp.130~141 (2003)
44. Moon WS, "Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma : Implications for angiogenesis", Hum Pathol, 37, pp.1324~1332 (2006)
45. Hopfner M, "Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma", J Hepatol, 41, pp.1008~1016 (2004)
46. Savic R, "Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer", PLoS One, 8, pp.e65620~ (2013)
47. Kusano H, "Antiproliferative effects of sorafenib and pegylated IFNalpha2b on human liver cancer cells in vitro and in vivo", Int J Oncol, 42, pp.1897~1903 (2013)

관련 논문AI추천